Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: orthopoxvirus infections therapeutics - TransTech Pharma/SIGA Technologies

Drug Profile

Research programme: orthopoxvirus infections therapeutics - TransTech Pharma/SIGA Technologies

Alternative Names: TTP 018

Latest Information Update: 23 Sep 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SIGA Technologies; TransTech Pharma
  • Class Small molecules; Viral vaccines
  • Mechanism of Action Peptide hydrolase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Orthopoxvirus infections

Most Recent Events

  • 21 Sep 2010 No development reported - Preclinical for Orthopoxvirus infections in USA (unspecified route)
  • 25 Jul 2007 TTP 018 is in preclinical development
  • 31 May 2004 This programme is still in active development - 17th International Conference on Antiviral Research (ICAR-2004)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top